Pulmonx

LUNG · NASDAQ

$1.82+$0.07 (+4.00%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.75

LUNG analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $3.47 (+90.5% upside)

Low: $2.53
Now: $1.82
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

LUNG analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
D. Boral Capital	Apr 30, 2026	Maintains	Buy	$14.00	29%
Canaccord Genuity	Mar 5, 2026	Maintains	Buy	$6.00 → $5.00	58%
D. Boral Capital	Mar 5, 2026	Maintains	Buy	$14.00	29%
D. Boral Capital	Feb 20, 2026	Maintains	Buy	$14.00	29%
D. Boral Capital	Nov 13, 2025	Maintains	Buy	$14.00	29%
Lake Street	Oct 28, 2025	Maintains	Buy	$8.00 → $4.00	36%
D. Boral Capital	Oct 28, 2025	Maintains	Buy	$16.00 → $14.00	29%

The case for and against

Updated Aug 25, 2026

Bull case

Pulmonx is expected to see a positive outlook in the long-term due to the company's strong product pipeline, with its Zephyr Valve and LungTraX Platform showing promising potential in the treatment of severe emphysema. Additionally, the company's cost restructuring initiatives and increasing international revenue are expected to improve profitability and help mitigate risk factors. In the short-term, the company may face challenges in the U.S. due to the current commercial reset, but its partnership with hospitals and increasing evidence of same-store productivity could support growth.

Bear case

Pulmonx is currently facing multiple challenges, as evident from their declining revenue from both the U.S. and international markets. In addition, their cash balance has decreased significantly over the past year, and their operating expenses remain high, leading to a narrow net loss. These issues, along with various risk factors, suggest that the company's outlook is negative in the near term, with limited growth potential.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.